secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001140361-25-029350
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore Q2 2025: KIMMTRAK revenue $98M (+30% YoY); net loss $10.3M
---------------------------------------------------------------------

- Q2 2025 net product sales of $98.0M, up 30% vs. $75.3M in Q2 2024; US sales $64.1M, Europe $33.0M.
- Net loss of $10.3M ($0.20 per share) compared to net loss of $11.6M ($0.23 per share) in Q2 2024.
- Cash, equivalents & marketable securities of $882.8M as of June 30, 2025; expects ~$65M in rebate payouts.
- Phase 3 TEBE-AM trial (cutaneous melanoma) on track to complete enrollment in 1H 2026.
- PRISM-MEL-301 (brenetafusp) dose selection expected in 2H 2025; IDMC recommended continue with no changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125029350/0001140361-25-029350-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036125029350/ef20053240_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-029350

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer